Suspension of trading
Valuation RAPT Therapeutics, Inc.
Stocks
RAPT
US75382E2081
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
16:00:00 2026-03-02 EST
|
5-day change | 1st Jan Change | ||
| 58.02 USD | +0.07% |
|
-.--% | +71.30% |
Company Valuation: RAPT Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 602.8 | 485 | 1,085 | 672 | 854.7 | 213.2 |
| Change | - | -19.54% | 123.77% | -38.08% | 27.19% | -75.05% |
| Enterprise Value (EV) 1 | 525.4 | 373.5 | 895.6 | 431.9 | 702.8 | -13.33 |
| Change | - | -28.92% | 139.81% | -51.77% | 62.71% | -101.9% |
| P/E | -2.79x | -9.01x | -14.5x | -7.69x | -8.16x | -0.5x |
| PBR | 8.24x | 4.7x | 5.82x | 2.77x | 5.81x | 1.1x |
| PEG | - | 0.1x | -0.9x | -3.9x | -0.4x | -0.11x |
| Capitalization / Revenue | - | 96,185,305x | 284,612,283x | 440,089,244x | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | -12.4x | -7.17x | -13.1x | -5.1x | -5.58x | 0.1x |
| EV / EBIT | -12x | -7.02x | -12.9x | -5.03x | -5.53x | 0.1x |
| EV / FCF | -23.9x | -16.7x | -26x | -10.8x | -13x | 0.34x |
| FCF Yield | -4.19% | -5.98% | -3.85% | -9.26% | -7.71% | 291% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -79.14 | -17.53 | -20.21 | -20.61 | -24.37 | -25.49 |
| Distribution rate | - | - | - | - | - | - |
| Net sales | - | 5.042 | 3.813 | 1.527 | - | - |
| EBITDA 1 | -42.3 | -52.09 | -68.21 | -84.75 | -125.8 | -134.9 |
| EBIT 1 | -43.63 | -53.21 | -69.21 | -85.8 | -127.1 | -136.1 |
| Net income 1 | -43 | -52.89 | -69.2 | -83.84 | -116.8 | -129.9 |
| Net Debt 1 | -77.38 | -111.5 | -189.7 | -240.1 | -152 | -226.6 |
| Reference price 2 | 220.88 | 158.00 | 293.84 | 158.40 | 198.80 | 12.64 |
| Nbr of stocks (in thousands) | 2,729 | 3,069 | 3,693 | 4,243 | 4,300 | 16,870 |
| Announcement Date | 3/30/20 | 3/11/21 | 3/10/22 | 3/14/23 | 3/7/24 | 3/6/25 |
1USD in Million2USD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 1.79B | |
| 20.63x | 7.28x | 14.62x | 1.44% | 70.24B | |
| 32.28x | 9.34x | 45.05x | 0.04% | 62.63B | |
| -76.7x | 14.8x | -71.37x | -.--% | 27.36B | |
| 29.77x | 6.32x | 16.41x | -.--% | 25.71B | |
| -15.03x | 5.62x | -7.06x | -.--% | 24.83B | |
| 26.45x | 5.03x | 16.73x | -.--% | 19.52B | |
| 44.88x | 16.47x | 33.42x | 0.34% | 15.51B | |
| 1267.62x | 36.68x | 797.93x | -.--% | 14.66B | |
| -15.8x | 3569.89x | -18.25x | -.--% | 14.69B | |
| Average | 146.01x | 407.94x | 91.94x | 0.2% | 27.7B | |
| Weighted average by Cap. | 77.53x | 200.44x | 52.40x | 0.4% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- RAPT Stock
- Valuation RAPT Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
